PT Pyridam Farma Tbk (PYFA.JK) Stock

PYFA.JK logo

PT Pyridam Farma Tbk

PYFA.JKIndonesia
Healthcare

Company profile

PT Pyridam Farma Tbk reported revenue of 2.76 trillion IDR for fiscal year 2025, and a net loss of 379.67 billion IDR. That is a net profit margin of -13.8% for fiscal year 2025. Its largest business segment, Pharmaceutical products, esthetic and toll products and toll manufacturing services, brought in 100% of segment revenue in fiscal year 2025; Australia was the largest region with 73%. Our analysis of its filings shows revenue growing from 702.07 billion IDR in fiscal year 2023 to 2.76 trillion IDR in fiscal year 2025, 98.3% a year on average. PT Pyridam Farma Tbk reports about 2,466 full-time employees.

What stands out

  • Revenue rose 43.7% in fiscal year 2025, from 1.92 trillion IDR in fiscal year 2024, after a rise of 173.6% the year before.
  • It reported a net loss in each of its last 3 fiscal years (2023 to 2025), after a profit of 275.24 billion IDR in fiscal year 2022.
  • Its net profit margin over the last four reported quarters was -11.3%, against a median of 8.9% for 5 listed companies of similar size in its industry.

Figures from company filings; latest fiscal year ended December 31, 2025.

About PT Pyridam Farma Tbk

PT Pyridam Farma Tbk engages in the pharmaceutical business in Australia, Indonesia, Philippines, Singapore, and India. The company operates through two segments, Pharmaceutical Products, Esthetic and Toll Manufacturing Services; and Medical Equipment segments. It supplies medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR - extraction kit and extractor machine, speciment bag, sterile container, PCR machine- Gentier 48, and tube stopper. The company also provides skin care and beauty products; medical support products; and other consumer health products in the form of syrups, tablets, and capsules; sterile and injection; and sanitizers and antiseptics. In addition, it offers antiseptic solutions, betadine antiseptic skin cleansers, Betadine Vaginal Douche, Cold defense nasal and throat sprays, feminine hygiene, Guardix SG, Mouthwash and Gargle, Salep antiseptic products. PT Pyridam Farma Tbk was founded in 1976 and is headquartered in Jakarta Selatan, Indonesia. PT Pyridam Farma Tbk operates as a subsidiary of Rejuve Global Investment Pte. Ltd.

Largest shareholders

  • Rejuve Global Investment Pte Ltd.60.46%
  • PT Asuransi Jiwa Starinvestama SA5.10%

Share of the company, as of September 25, 2026

Leadership

  • Yan Gwan Lee — President Director, 62
  • Paulus Widjanarko Brotosaputro — COO, Head of Pharmacovigilance & President Commissioner, 60
  • Yenfrino Gunadi — CFO & Director, 38
  • Antes Eko Prasetio — Chief Commercial Officer & Director
  • Sinta Lestari Ningsih — VP of Finance, Accounting & Tax and Director

How much revenue does PT Pyridam Farma Tbk make?

PT Pyridam Farma Tbk reported 2.76 trillion IDR in revenue for fiscal year 2025, up 43.7% from 1.92 trillion IDR in fiscal year 2024.

What is PT Pyridam Farma Tbk's largest business segment?

Pharmaceutical products, esthetic and toll products and toll manufacturing services, with 2.75 trillion IDR or 100% of segment revenue in fiscal year 2025. Next: Medical Equipment Products (under 1%).

Where does PT Pyridam Farma Tbk make most of its revenue?

Australia: 73% of revenue by region in fiscal year 2025, followed by Indonesia (26%).

What companies are similar to PT Pyridam Farma Tbk?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include PT Tempo Scan Pacific Tbk (TSPC.JK), PT Darya-Varia Laboratoria Tbk (DVLA.JK), PT Merck Tbk (MERK.JK), PT Indofarma Tbk (INAF.JK).

How has PT Pyridam Farma Tbk's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 630.53 billion IDR; FY2022, 715.43 billion IDR; FY2023, 702.07 billion IDR; FY2024, 1.92 trillion IDR; FY2025, 2.76 trillion IDR.

Has PT Pyridam Farma Tbk made a profit in recent years?

Net income by fiscal year: FY2021, 5.48 billion IDR; FY2022, 275.24 billion IDR; FY2023, a loss of 85.22 billion IDR; FY2024, a loss of 330.25 billion IDR; FY2025, a loss of 379.67 billion IDR. It reported a net loss in 3 of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees2,466
FoundedJan 1, 1976
IPO DateOct 16, 2001
IPO StatusPublic
HeadquartersJakarta Selatan, Indonesia
FoundersIr. Sarkri Kosasih
ExchangeJakarta
TimezoneAsia/Jakarta (WIB)

Contact & Links

Address
Sinar Mas Land Plaza Sudirman, Jakarta Selatan, 12920
Phone
62 21 5099 1067
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “PT Pyridam Farma Tbk (PYFA.JK)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/PYFA.JK

LinkedInLinkedInXXYouTubeYouTube